ISD Immunotech has announced the appointment of Gert Bolwig as the company’s Chief Executive Officer.
Gert Bolwig will be succeeding Ingelise Sunders who has acted as Executive Chairman. Ms. Saunders will continue as Chairman of the Board.
“We are delighted to have Gert join our company,” says Ingelise Saunders, Chairman of the Board. “Gert is an experienced life science professional who complements the team and is perfectly positioned to lead the company.”
Read more: Personalized therapy for severe lupus
Dr. Bolwig brings expertise in business development, fundraising and program management. He has more than two decades of industry and leadership experience from Biotech and Pharma, including Orphazyme and Nycomed, states the company.
He is also an investment advisor for a life science fund and has been a consultant for a several biotech companies.
“I am privileged to join ISD at this exciting time,” says Gert Bolwig. “The team has produced outstanding work and built a global network of world-class scientific and medical advisors. We now look forward to executing our plan to hopefully provide the sufferers of this very serious chronic disease, most of whom are women of child-bearing age, with a new and efficacious treatment option.”
Photo of Gert Bolwig: ISD Immunotech